(Q49079002)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10726726%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

title

Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10726726%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

0 references

P van Cauwenberge

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10726726%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

C Bachert

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10726726%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

G Passalacqua

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10726726%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

J Bousquet

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10726726%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

W J Fokkens

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10726726%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

P H Howarth

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10726726%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

V Lund

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10726726%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

H J Malling

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10726726%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

N Mygind

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10726726%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

D Passali

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10726726%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

G K Scadding

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10726726%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

D Y Wang

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10726726%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

publication date

1 February 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10726726%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10726726%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

volume

55

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10726726%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10726726%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

page(s)

116-134

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10726726%20AND%20SRC:MED&resulttype=core&format=json

Prevalence of atopy and pollinosis in the adult population of Switzerland (SAPALDIA study). Swiss Study on Air Pollution and Lung Diseases in Adults

5 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Overview of comorbid associations of allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Pathophysiology of allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Adhesion molecules of allergic inflammation: recent insights into their functional roles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Regulation of proinflammatory cytokines in seasonal allergic rhinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Dust mites: immunology, allergic disease, and environmental control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Chemical treatment of carpets to reduce allergen: a detailed study of the effects of tannic acid on indoor allergens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Benzyl benzoate moist powder: investigation of acaricidal [correction of acarical] activity in cultures and reduction of dust mite allergens in carpets

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Reducing domestic exposure to dust mite allergen reduces bronchial hyperreactivity in sensitive children with astham

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Allergen-avoidance measures in homes of house-dust-mite-allergic asthmatic patients: effects of acaricides and mattress encasings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

House dust mite control measures in the management of asthma: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Airborne cat allergen (Fel d I). Environmental control with the cat in situ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Comparative trial of two non-sedative H1 antihistamines, terfenadine and astemizole, for hay fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

The nasal allergic reaction: observations on the role of histamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Effect of H1 and H2 antagonists on nasal symptoms and mediator release in atopic patients after nasal allergen challenge during the pollen season

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Profile of ragweed hay fever symptom control with terfenadine started before or after symptoms are established

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Cetirizine. A review of its pharmacological properties and clinical potential in allergic rhinitis, pollen-induced asthma, and chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Efficacy and safety of mizolastine in seasonal allergic rhinitis. The Rhinase Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Terfenadine. A review of its pharmacodynamic properties and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

The effect of azelastine on the early allergic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Effects of loratadine on anti-IgE-induced inflammation, histamine release, and leukocyte recruitment in skin of atopics

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Psychometric aspects of antihistamines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Azelastine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Topical levocabastine is more effective than sodium cromoglycate for the prophylaxis and treatment of seasonal allergic conjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Antihistamines: topical vs oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Faster onset of action with topical levocabastine than with oral cetirizine

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Allergic rhinitis and inflammation: the effect of nasal corticosteroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Mast cells and mediators in the nasal mucosa after allergen challenge. Effects of four weeks' treatment with topical glucocorticoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Once-daily mometasone furoate nasal spray: efficacy and safety of a new intranasal glucocorticoid for allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

A placebo‐controlled study of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate in perennial rhinitis: efficacy in allergic and non‐allergic perennial rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Budesonide. An updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Intranasal fluticasone propionate. A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

A double-blind comparison of nasal budesonide and oral astemizole for the treatment of perennial rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Seasonal allergic rhinitis and depot injection of a corticosteroid. Evaluation of the efficacy of medication early and late in the season based on detailed symptom recording

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Intramuscular betamethasone dipropionate vs. oral prednisolone in hay fever patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Oral methylprednisolone acetate (Medrol Tablets) for seasonal rhinitis: examination of dose and symptom response

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Inhibition of neutrophil and eosinophil induced chemotaxis by nedocromil sodium and sodium cromoglycate

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Nedocromil sodium. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of reversible obstructive airways disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Vascular effects of topical oxymetazoline on human nasal mucosa

21 January 2018

2 references

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

21 January 2018

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

The parasympathetic secretory nerves of the nose of the cat.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Ordinary and high-dose ipratropium in perennial nonallergic rhinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Intranasal ipratropium: A new treatment for perennial rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Control of the hypersecretion of vasomotor rhinitis by topical ipratropium bromide

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

The major allergen content of allergenic preparations reflect their biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

The Present State of our Knowledge of Hay-Fever: Being a Paper Presented at the Berlin Congress of the Royal Institute of Public Health

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Fatalities from immunotherapy (IT) and skin testing (ST)

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

A clinical overview of Tilarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Childhood Cushing's syndrome induced by betamethasone nose drops, and repeat prescriptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Pharmacokinetic Optimisation of Histamine H1-Receptor Antagonist Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

Epidemiology of allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Sedation in allergic rhinitis is caused by the condition and not by antihistamine treatment

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Learning impairment and allergic rhinitis.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

1 reference

7 January 2021

Immunohistology of the nasal mucosa in seasonal allergic rhinitis: increases in activated eosinophils and epithelial mast cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Inflammatory mediators in naturally occurring rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Nasal mucosal response to repeated challenges with pollen allergen

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Allergen exposure induces the activation of allergen-specific Th2 cells in the airway mucosa of patients with allergic respiratory disorders

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Chemokines in seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

The relative risks of sensitivity to grass pollen, house dust mite and cat dander in the development of childhood asthma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Reduction of house dust mite allergen levels in the home: use of the acaricide, pirimiphos methyl.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Cat shedding of Fel d I is not reduced by washings, Allerpet-C spray, or acepromazine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Correlations between complaints, inflammatory cells and mediator concentrations in nasal secretions after nasal allergen challenge and during natural allergen exposure

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Clinical comparison of histamine H1-receptor antagonist drugs.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Effect of cetirizine and prednisolone on cellular infiltration and cytokine mRNA expression during allergen-induced late cutaneous responses

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Non-sedating antihistamines and cardiac arrhythmia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Double-blind comparison of levocabastine eye drops with sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Local Effect of Intranasal Beclomethasone Dipropionate Aerosol in Hay Fever

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Influence of prolonged treatment with topical corticosteroid (fluticasone propionate) on early and late phase nasal responses and cellular infiltration in the nasal mucosa after allergen challenge

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

A dose-ranging study of fluticasone propionate aqueous nasal spray for seasonal allergic rhinitis assessed by symptoms, rhinomanometry, and nasal cytology

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

The efficacy and tolerability of fluticasone propionate aqueous nasal spray in children with seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone diproprionate

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

A double-blind comparison of fluticasone propionate aqueous nasal spray, terfenadine tablets and placebo in the treatment of patients with seasonal allergic rhinitis to grass pollen

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Effects of topical budesonide and levocabastine on nasal symptoms and plasma exudation responses in seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Prevention of pollen rhinitis symptoms: comparison of fluticasone propionate aqueous nasal spray and disodium cromoglycate aqueous nasal spray. A multicenter, double-blind, double-dummy, parallel-group study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

A 1-year placebo-controlled study of intranasal fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis: a safety and biopsy study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Nasal septal perforation associated with topical corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Lack of hypothalamic-pituitary-adrenal axis suppression with once-daily or twice-daily beclomethasone dipropionate aqueous nasal spray administered to patients with allergic rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

A comparison of effects of triamcinolone acetonide aqueous nasal spray, oral prednisone, and placebo on adrenocortical function in male patients with allergic rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Fluticasone propionate: topical or systemic effects?

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Budesonide aqueous nasal spray and pressurized metered dose inhaler in the treatment of adult patients with seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Allergen-induced changes in the nasal mucous membrane in seasonal allergic rhinitis: effect of nedocromil sodium

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Levocabastine nasal spray better than sodium cromoglycate and placebo in the topical treatment of seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Tilarin in combination with astemizole

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Product characteristics and pharmacokinetics of intranasal ipratropium bromide

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Treatment of perennial secretory rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Ipratropium (Atrovent) in the treatment of vasomotor rhinitis of elderly patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Onset and duration of inhibition of ipratropium bromide nasal spray on methacholine-induced nasal secretions

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

The anticholinergic treatment of allergic perennial rhinitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Long-term treatment of perennial allergic rhinitis with ipratropium bromide nasal spray 0.06%

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Ipratropium treatment for rhinorrhoea in patients with perennial rhinitis. An open follow-up study of efficacy and safety

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Long-term safety and efficacy study of intranasal ipratropium bromide

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Immunotherapy as an effective tool in allergy treatment

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

A prospective safety-monitoring study of immunotherapy with biologically standardized extracts

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Systemic reactions occurring during immunotherapy with standardized pollen extracts

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Is there a role for immunotherapy in the treatment of asthma? Yes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Is there a role for immunotherapy in the treatment of asthma? No

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

1 reference

7 January 2021

Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Prevention of asthma with ketotifen in preasthmatic children: a three-year follow-up study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

Comparison of the efficacy and tolerability of topical levocabastine and sodium cromoglycate in the treatment of seasonal allergic rhinoconjunctivitis in children

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021

The long-term effects of capsaicin aqueous spray on the nasal mucosa.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1398-9995.2000.00526.X

7 January 2021